THERENVA

Their core work

THERENVA is a French medical software SME based in Rennes specialising in patient-specific cardiovascular simulation — the computational modelling of blood flow, vessel mechanics, and cardiac device behaviour in virtual replicas of individual patients. Their work sits at the intersection of biomechanics, clinical data, and software engineering, producing tools that help medical device developers and clinicians predict how a device or treatment will perform before it reaches the operating room. In VPH-CaSE they contributed to simulation and experimentation frameworks for personalised medical devices using Virtual Physiological Human methods, while in EurValve they supported the development of decision-support software for heart valve disease management. Their core value proposition is turning patient imaging and clinical data into actionable, quantitative predictions for cardiovascular interventions.

What they specialise in

How they've shifted over time

THERENVA's two projects both started within one year of each other (2015–2016) and ran concurrently through to 2019, so it is not possible to draw a clear before-and-after trajectory from the timeline alone. The projects do reveal a subtle shift in emphasis: VPH-CaSE leaned toward device-side simulation and experimental validation, while EurValve moved the focus toward the clinical workflow — turning simulation results into structured decision support for clinicians treating valve disease. This suggests a company broadening from pure modelling tools toward integrated clinical software, though with only two data points the signal is weak.

THERENVA appears to be moving up the clinical value chain — from back-end simulation infrastructure toward front-end decision tools that clinicians can use directly, which would position them closer to the medical software product market.

How they like to work

THERENVA has never led an H2020 project — in both cases they joined as a participant within larger research consortia. With 25 unique partners across 8 countries spread across just 2 projects, they operate inside sizeable, multi-institutional networks rather than in small bilateral arrangements. This profile is typical of a specialist software SME: they bring a specific technical module (simulation engine, decision-support tool) that larger academic–clinical consortia need but cannot build in-house, without taking on the administrative overhead of coordination.

THERENVA has engaged with 25 distinct partner organisations across 8 countries through just 2 projects, suggesting they were embedded in well-connected, pan-European health research consortia. No single dominant geography is apparent from the data, pointing to a genuinely European collaboration footprint.

What sets them apart

THERENVA occupies a rare niche as a small French software company that combines biomedical engineering rigour with commercial software development, focused tightly on cardiovascular simulation — a field most competitors approach from either a pure academic or large medtech-company angle. Being an SME makes them agile enough to embed into diverse consortia as a technical module provider without the overhead of a large corporation, while their project track record demonstrates they can operate within the regulatory and scientific standards of EU health research. For consortium builders, they fill the gap between research-grade simulation code and validated, deployable clinical decision tools.

Highlights from their portfolio

• EurValve
  The largest of their two funded projects (EUR 302,739) and the one most directly targeting clinical deployment — personalised decision support for heart valve disease represents a clear path toward a marketable medical software product.
• VPH-CaSE
  Situates THERENVA within the established Virtual Physiological Human research community, signalling methodological credibility and connections to Europe's core biomedical modelling network.